


<!DOCTYPE html>
<html lang="en">
<head><script>(function (w, d, s, l, i) {
 w[l] = w[l] || []; w[l].push({
  'gtm.start':
  new Date().getTime(), event: 'gtm.js'
 }); var f = d.getElementsByTagName(s)[0],
 j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayerCIT', 'GTM-W6MJHWF');</script>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<meta name="description" content="View dosing and administration info for Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension. See full Prescribing and Safety Information." />
	<meta name="keywords" />
	<meta name="format-detection" content="telephone=no">
	<meta name="viewport" content="width=device-width, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no">

	<title>Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension Dosing &amp; Administration | HCP</title>

		<script language="javascript" type="text/javascript" src="http://www.pharma.us.novartis.com/privacy-lightbox/privacy-update-controller.js"></script>
		<script>



			var displayGlobalPPDisclaimer = false;
		</script>


	<link href="../../../../bundles/css/master%3Fv=DFPHbovhUMiL9Dn52heMUNXymBxWvano9tAsQ64HmSY1.css" rel="stylesheet"/>

	<script src="../../../../bundles/script/jquery%3Fv=4Fx6N4x0ohHzU3HBQJk1GtgRoUo_IXc-CWFU9ADPAB81"></script>



	

  <!-- V4 JS core and at least one video plugin is required. Plugins such as skin, discovery and Advertising need to be loaded separately -->
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/core.min.js"></script>
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/video-plugin/main_html5.min.js"></script>
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/video-plugin/osmf_flash.min.js"></script>
 <!-- <script src="//player.ooyala.com/static/v4/stable/4.6.9/video-plugin/bit_wrapper.min.js"></script> -->
  <!-- Change these html5-skin.min.css and html5-skin.min.js to your local build if necessary -->
  <script src="http://player.ooyala.com/static/v4/stable/4.8.5/skin-plugin/html5-skin.min.js"></script>
  <link rel="stylesheet" href="http://player.ooyala.com/static/v4/stable/4.8.5/skin-plugin/html5-skin.min.css" />


 <link href="../../../../bundles/css/brands%3Fv=MJ1cSwv0ph-T8cA6caKmdNsA7L_OcnSUI801YYiuxLo1.css" rel="stylesheet"/>

 

  <style type="text/css">
 .brandColor, .left-teaser a, .uso-brand-detailmenu li{
  color:#19a2b1;
 }
 a.brandColor, a.brandColor:hover, a.brandColor:active {
  color:#19a2b1;
 }
 .brandBackColor {
  background-color:#19a2b1;
 }
 .select-indication a.brandColor,
 .select-indication a.brandColor:hover {
  color: #19a2b1;
 }
 .geo-panel .glyphicon {
  color: #19a2b1;
 }
 .uso-accordion-title:after {
  border-color: #19a2b1 !important;
 }

  </style>


		




		<script>
			window.dataLayerOnco = window.dataLayerOnco || [];

			var preDataLayerOnco = {"environment":"STAGE","department":undefined,"indication":"carcinoid-syndrome","brand":"sandostatin-lar-depot","type":undefined,"sectionLevel1":"products","sectionLevel2":"carcinoid-syndrome","sectionLevel3":"dosing-administration","status":undefined,"name":"products : sandostatin-lar-depot : carcinoid-syndrome : dosing-administration"};
			preDataLayerOnco.department = 'oncology';
			preDataLayerOnco.type = 'hcp';
			preDataLayerOnco.status = 200;
			dataLayerOnco.push({
				'page':preDataLayerOnco
			});
		</script>
		<!-- Google Tag Manager -->
		<script>
(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
		new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
		j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
		'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
		})(window,document,'script','dataLayerOnco','GTM-PH7LL77');</script>
		<!-- End Google Tag Manager -->


</head>
<body>

		<!-- Google Tag Manager -->
		<noscript>
			<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PH7LL77" height="0" width="0" style="display:none;visibility:hidden"></iframe>
		</noscript>
		<!-- End Google Tag Manager -->

	<script type="text/javascript">

  $(document).ready(function () {

/**/
// global vars
var path = window.location.pathname.split('/'),
pageName,
channel,
brandProduct,
campaign;

/**/
// URL / dataLayer functions
function getQueryVariable(variable) {
 var query = window.location.search.substring(1);
 var vars = query.split('&');
 for (var i = 0; i < vars.length; i++) {
  var pair = vars[i].split('=');
  if (decodeURIComponent(pair[0]) == variable) {
return decodeURIComponent(pair[1]);
  } else {
return "";
  }
 }
}

function dataLayerFunction() {
 $('a').not('#brand-detail-page .uso-tab-menu a').not('.onePageTemplatePage .uso-tab-menu a').on('click', function () {
  var $this = $(this);
  if ($this.parents('.selectpicker').length == 0) {

var pattern = /^.*\.(docx|DOCX|xlsx|XLSX|xls|doc|DOC|pdf|PDF)$/;
if ($this.attr('href') !== undefined) {
 var ext = $this.attr('href').match(pattern);

 if (ext != null) {
  if (ext[1] == 'docx' || 'DOCX' || 'xlsx' || 'XLSX' || 'xls' || 'doc' || 'DOC' || 'pdf' || 'PDF') {
fileDownload = $this.attr('href');
dataLayer.page.fileDownload = fileDownload;
  }
 }
}
  }
 })

 $('.research-landing-page a').on('click', exitLink);
 $('#uso-product-page a').on('click', exitLink)
 function exitLink() {
					var href = $(this).attr('href');
					if (typeof href != 'undefined') {
						var boolExternalLink = isExternalLink(href);
						if (boolExternalLink) {
							dataLayer.page.exitLink = href;
						}
					}
 }
 function isExternalLink(href) {
  var dataTarget = $(this).data('target');
  var domain = href.split("?");
  if (domain[0].indexOf('http') != -1 && domain[0].indexOf(window.location.hostname) == -1 && dataTarget != "none") {
return true;
  } else {
return false;
  }
 }
}

/**/
// set dataLayer vars
if (path.length == 2) {
 pageName = "home";
 channel = "";
} else {

 var hasEndSlash = (window.location.pathname.lastIndexOf('/') == window.location.pathname.length - 1);
 if (hasEndSlash) {
  if (path[path.length - 1] == "") {
path.pop();
  }
 }
 path = path.slice(1);
 pageName = path.join(':').toLowerCase();
 if (path.length == 1) {
  channel = pageName;
 } else {
  channel = path[0];
 }
}
// sets the last url location value to brandProduct
brandProduct = window.location.pathname.split('/');
brandProduct = brandProduct[brandProduct.length - 2];
if (brandProduct == "")
 brandProduct = "home";

campaign = getQueryVariable("site");

dataLayerFunction();

/**/
// build dataLayer
dataLayer = {
 page: {
  pageName: 'hcp' + ':' + pageName,
  channel: channel,
  pageCategory: 'HCP',
  eVar20: brandProduct,
  campaign: campaign
 }
};

  });
	</script>
	<main>
				



		
		<a href="http://usoncohcp-web.stage.novartis.episerverhosting.com/"></a>
		<a href="http://usoncohcp-web.stage.novartis.episerverhosting.com/"></a>
		
		<a href="http://localhost:38015/"></a>
		<a href="http://localhost:38015/"></a>
		
		<a href="http://localhost:38015/?link=hgjhgjhg"></a>
		<a href="http://localhost:38015/?link=hgjhgjhg"></a>

		<div id="movingOnDisclaimer" class="modal fade" data-backdrop="static">
			<div class="modal-dialog">
				<div class="modal-content">
					<div class="modal-header">
						<button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button>
						<img class="center-block" src="../../../../Static/img/global/uso-logo-header.png" />
					</div>
					<div class="modal-body">

						<p>
							We’re moving on!<br />
							Join us at <span data-dismiss="modal" class="hcpLink">www.hcp.novartis.com</span>—our new location for health care professionals to find product, access, and medical information. Now you can find the tools you need to help manage your patients, all in one place!
						</p>
						<p>You’ll have access to the site in a moment, or click <span class="hcpLink" data-dismiss="modal">continue</span> to  close this message and advance directly to the site.</p>

					</div>
					<div class="modal-footer">
						<div class="disclaimer-omap">
							12/15 ONC-1130276
						</div>
					</div>
				</div>
			</div>
		</div>

		<div id="uso-page">
			
			<div><div>


<div class="container-fluid container-header">
 <nav class="navbar navbar-default">
  <div class="uso-mobile-nav-header visible-xs-block visible-sm-block visible-md-block">This site is for US health care professionals only.</div>

  <div style="position:relative;">
<div id="uso-mobile-search-block">
 <input id="uso-mobile-search-input" type="text" class="uso-search-header-mobile clearable" placeholder="Search" />
</div>
<div class="navbar-header  ">
 <div class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false" aria-controls="navbar" data-link="/">
  <span class="sr-only">Toggle navigation</span>
  <img class="uso-nrts-logo" src="../../../../globalassets/novartis-logo-111516.svg" alt="Novartis logo" />
 </div>
 <a class="navbar-brand visible-lg-block visible-lg-block" href="http://usoncohcp-admin.stage.novartis.episerverhosting.com/" title="Novartis logo"><img class="uso-nrts-logo" src="../../../../globalassets/novartis-logo-111516.svg" alt="Novartis logo" /></a>
	
						<button id="uso-brandheader-mobile-btn" class="hidden-lg navbar-toggle collapsed" type="button" data-toggle="collapse" data-target="#uso-brandheader-mobile-menu nav">
							<span class="sr-only">Toggle navigation</span>
							<span class="icon-bar"></span>
							<span class="icon-bar"></span>
							<span class="icon-bar"></span>
						</button>
					<div class="tagline">
						<span class="uso-navbar-brand-desc visible-lg-inline-block">This site is for US health care professionals only.</span>
					</div>

  <div id="uso-brandheader-mobile-menu" class="hidden-lg">
<nav class="navbar-collapse bs-navbar-collapse collapse" aria-expanded="false">
  <p class="uso-brandheader-indication">For: Severe Diarrhea and Flushing Associated With Carcinoid Syndrome</p>
 <ul class="nav navbar-nav">
  <li><a href="../efficacy/index.html">Efficacy</a></li>
  <li><a href="../safety-profile/index.html">Safety Profile</a></li>
  <li><a href="index.html">Dosing &amp; Administration</a></li>
  <li><a href="../nurse-center/index.html">On-Demand Training &amp; Resources</a></li>
  <li><a href="../mechanism-of-action/index.html">Mechanism of Action</a></li>
  <li><a href="../access/index.html">Access</a></li>
  <li><a href="../patient-resources/index.html">Patient Resources</a></li>
 </ul>
</nav>
  </div>
		</div>
 </div>
</nav>
</div>
<input id="uso-hidden-search-page-url" type="hidden" value="/search/" /></div></div>
			





<div class="container">
 <div class="row brandHeader">
  <div class="col-lg-6 col-md-6 col-xs-12" title="Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension logo">
<a class="backLink" href="../index.html" title="Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension logo"><i class="fa fa-angle-left"></i></a>
<img class="brandLogo" src="../../../../globalassets/products/sandostatin-lar/sandostatin-header-logo-2019-01-24.png" alt="Sandostatin&#174; LAR Depot (octreotide acetate) for injectable suspension logo" />
  </div>
<div class="col-lg-6 col-md-6 col-xs-12 indicationsSelector clearfix">
 <b>For:</b>

 <div id="selector-container">
  <div class="current-indication">
<span>Severe Diarrhea and Flushing Associated With Carcinoid Syndrome</span>
  </div>
  <ul class="select-indication">

  <li class=""><a class="" href="../../acromegaly/index.html" target="_self" data-target="">Acromegaly</a></li>
  </ul>
 </div>
</div>

 </div>
</div>
<div class="container-fluid">
 <div class="row rowIsi ">
  <div class="col-lg-12 isiLinkContainer brandBackColor">
 <a href="index.html#important-safety-info" class="isiLink arrow" >
IMPORTANT SAFETY INFORMATION AND INDICATION </a>
  </div>
 </div>
 
</div>

<div class="container">
 <div class="hidden-lg hidden-md row">
  <div class="col-xs-12">
<h1 class="uso-brand-detail-mobiletitle"><a class="backLink brandColor" href="../index.html"><i class="fa fa-angle-left"></i> Dosing &amp; Administration</a></h1>
  </div>
 </div>
</div>
<div id="brand-detail-page" class="container-fluid brand-container">

 <div class="container">
  <div class="row mainContent">
<div class="teasers-col ">
<ul class='uso-brand-detailmenu visible-lg visible-md'>
<li>
<a href="../efficacy/index.html">Efficacy</a>
</li>
<li>
<a href="../safety-profile/index.html">Safety Profile</a>
</li>
<li>
Dosing & Administration
</li>
<li>
<a href="../nurse-center/index.html">On-Demand Training &amp; Resources</a>
</li>
<li>
<a href="../mechanism-of-action/index.html">Mechanism of Action</a>
</li>
<li>
<a href="../access/index.html">Access</a>
</li>
<li>
<a href="../patient-resources/index.html">Patient Resources</a>
</li>
</ul>

  <div class="teasers-sticky">
<div class='left-teaser left-teaser-detail'>



<div class="quick-links-block clearfix">
 <ul>

<li>
 <a class="quick-link" href="https://www.novartis.us/sites/www.novartis.us/files/sandostatin_lar.pdf">
<span class="icon"><img  src="../../../../globalassets/download_link_icon.svg" /></span>
  <span class="quick-link-text ">Prescribing Information</span>
 </a>
</li>
<li>
 <a class="quick-link" href="https://www.us.sandostatin.com/carcinoid-syndrome">
<span class="icon"><img  src="../../../../globalassets/products/sandostatin-lar/carcinoid/list-icon-link.png" /></span>
  <span class="quick-link-text ">Visit Patient Site</span>
 </a>
</li>
<li>
 <a class="quick-link" href="http://usoncohcp-admin.stage.novartis.episerverhosting.com/link/70abc9df0e1840aeaebe563e377df611.aspx?id=10721">
<span class="icon"><img  src="../../../../globalassets/products/sandostatin-lar/carcinoid/list-icon-talk.png" /></span>
  <span class="quick-link-text ">Training &amp; Resources</span>
 </a>
</li>
<li>
 <a class="quick-link" href="http://usoncohcp-admin.stage.novartis.episerverhosting.com/link/d9831d78f7984e00adcf3b73fd501c38.aspx?id=70255">
<span class="icon"><img  src="../../../../globalassets/products/sandostatin-lar/carcinoid/list-icon-pay.png" /></span>
  <span class="quick-link-text ">Patient Services</span>
 </a>
</li> </ul>
</div>
</div>
<div class='left-teaser left-teaser-detail'>

<div class="quick-info-teaser-ISI">
 <div>
<strong class="brandColor">Important Safety Information</strong>

<div class="content">
 <p><strong>Warnings and Precautions</strong> Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...</p>
</div>

  <a href="index.html#important-safety-info" class="isiLink isiLinkSUB">
<strong class="brandColor">See More</strong>
  </a>
 </div>
</div>




</div>

  </div>
 <div class="teasers">
<div class='left-teaser left-teaser-detail'>

<div class="quick-info-teaser-block-indication">

<p><strong class="brandColor">Indication</strong> Sandostatin<sup>®</sup> LAR Depot (octreotide acetate) for injectable suspension is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate-release <span style="white-space: nowrap;">Sandostatin<sup>®</sup> (octreotide acetate)</span> Injection has been shown to be effective and tolerated. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.</p>
</div>
</div>

 </div>
</div>

<div class="content-col col-lg-8 col-md-7 col-sm-12 col-xs-12">
 <div class="uso-brand-detail-main">
  <h1  class="hidden-xs hidden-sm brandColor">Dosing &amp; Administration</h1>
<ul class='uso-tab-menu clearfix'>
<li>
<a data-target='flexible-dosing'>Flexible Dosing</a>
</li>
<li>
<a data-target='mixing--administration'>Mixing & Administration</a>
</li>
</ul>

  <div class="uso-brand-details"><div class="uso-brand-detailcontent">



<a name='flexible-dosing'></a>
<main>
	


<h3  class="brandColor">Flexible Dosing</h3>

<h4 ></h4>

<div class="description">
 <p ></p>
</div>

<div class="content">
 
</div>




<div class="row">

 


</div>



















</main></div><div class="uso-brand-detailcontent">



<div id="image-full-half-block-71787" class="image-full-half-block" data-hvce="" data-hvce-description="">
 <style>
		#image-full-half-block-71787 .desktopImg {
			display: inline-block;
		}

  #image-full-half-block-71787 .mobileImg {
			display: none;
		}

@media screen and (max-width: 1023px) { #image-full-half-block-71787 .desktopImg { display: none; }  #image-full-half-block-71787 .mobileImg {display: block;}} </style>


  <h3  class="brandColor"></h3>
  <div class="content">

  </div>

<div class="img-container">
 <img class="img-responsive desktopImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_dosing_header_banner_d.jpg" />
  <img class="img-responsive mobileImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_dosing_header_banner_m.jpg" />
 </div>
</div></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <h4><strong>Multiple Dosing Options Can Help Effectively Manage Patients' Symptoms<sup>1</sup></strong></h4>
<p>&nbsp;</p>
<p>Flexible dosing with 10&nbsp;mg, 20&nbsp;mg, and 30&nbsp;mg options allow for up or down titration with Sandostatin<sup>®</sup> LAR Depot (octreotide acetate) for injectable suspension in 10-mg increments from the recommended starting dose of 20&nbsp;mg. Sandostatin LAR Depot should be administered by a trained health care provider.</p>
<ul>
<li>If symptoms are adequately controlled on 20 mg, you may consider a dose reduction to 10&nbsp;mg</li>
<li>If symptoms are not adequately controlled on 20 mg, you are able to increase the dose to 30&nbsp;mg</li>
<li>Doses higher than 30&nbsp;mg are not recommended</li>
</ul>
<p>&nbsp;</p>
<h4><strong>Dosing with Sandostatin LAR Depot</strong></h4>
</div></div><div class="uso-brand-detailcontent">



<a name=''></a>
<main>
	

<h3  class="brandColor"></h3>

<h4 ></h4>

<p ></p>




 <style type="text/css">
  .uso-brand-detail-player { position: relative; }
  .uso-brand-detail-player-container{padding-bottom:56.25%;}
#player-67055 .oo_promo{background-color:#ffffff;}

 </style>

 <div class="video-player-wrapper Kaltura optitle" data-hvce="" data-hvce-description="">
<div class="video-player-thumbnail" id="video-thumb-67055" style="background-image: url(../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110500_dosing_video_thumb5.jpg)">
 <a class="video-play-icon"><span class="play-icon">h</span></a>
</div>
  <div id="1559887866" class="uso-brand-detail-player" data-targetId="1559887866-player" data-wid="_2076321" data-playerId="kaltura_player_1559887866" data-partnerId="2076321" data-uiconfId="40166251" data-entryId="1_d94dr7hp" data-kalturaCss="" data-thumbnailUrl="/globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110500_dosing_video_thumb5.jpg"  data-brandTheme="/modules/KalturaPlayerBrandColors/?BrandColor=19a2b1"  data-videoName="Dosing with Sandostatin LAR Depot">
<div class="inner">
 <div id="1559887866-player" class="embed-responsive embed-responsive-16by9"></div>
</div>
  </div>
 </div>
 <script id="KalturaScript" src="http://cdnapisec.kaltura.com/p/2076321/sp/207632100/embedIframeJs/uiconf_id/40166251/partner_id/2076321"></script>







<div class="row">

 


</div>


</main></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <p>&nbsp;</p>
<h4 style="margin-bottom: 10px;"><strong>Utilizing the Full Line of Sandostatin<sup>1</sup></strong></h4>
<p>Sandostatin<sup>®</sup> (octreotide acetate) Immediate-Release Injection and Sandostatin LAR Depot can be used to initiate treatment, titrate treatment, and treat flare-ups. After an initial 2-week starting dose, patients who respond to and tolerate Sandostatin Immediate-Release Injection may switch to Sandostatin LAR Depot, which offers dosing once every 4 weeks.</p>
<ul>
<li>Short-acting Sandostatin Immediate-Release Injection should be continued for at least 2 weeks following initial injection of Sandostatin LAR Depot 20&nbsp;mg</li>
<li>After 2 months, adjust dose of Sandostatin LAR Depot based on symptom control</li>
<li>Despite good overall control of symptoms, patients may experience periodic exacerbation of symptoms. During these periods, they may be given Sandostatin Immediate-Release Injection for a few days at the dosage they were receiving prior to switching to Sandostatin LAR Depot, until symptoms are again controlled</li>
</ul>
</div></div><div class="uso-brand-detailcontent">



<div id="image-full-half-block-71790" class="image-full-half-block" data-hvce="" data-hvce-description="">
 <style>
		#image-full-half-block-71790 .desktopImg {
			display: inline-block;
		}

  #image-full-half-block-71790 .mobileImg {
			display: none;
		}

@media screen and (max-width: 1023px) { #image-full-half-block-71790 .desktopImg { display: none; }  #image-full-half-block-71790 .mobileImg {display: block;}} </style>


  <h3  class="brandColor"></h3>
  <div class="content">

  </div>

<div class="img-container">
 <img class="img-responsive desktopImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_sds_vials_d.png" />
  <img class="img-responsive mobileImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_sds_vials_m.png" />
 </div>
</div></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <p>&nbsp;</p>
<h4>Dosing Flowchart<sup>1</sup></h4>
</div></div><div class="uso-brand-detailcontent">



<div id="image-full-half-block-71791" class="image-full-half-block" data-hvce="" data-hvce-description="">
 <style>
		#image-full-half-block-71791 .desktopImg {
			display: inline-block;
		}

  #image-full-half-block-71791 .mobileImg {
			display: none;
		}

@media screen and (max-width: 1023px) { #image-full-half-block-71791 .desktopImg { display: none; }  #image-full-half-block-71791 .mobileImg {display: block;}} </style>


  <h3  class="brandColor"></h3>
  <div class="content">

  </div>

<div class="img-container">
 <img class="img-responsive desktopImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_dosing_flow_chart_d.jpg" />
  <img class="img-responsive mobileImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_dosing_flow_chart_m.jpg" />
 </div>
</div></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <p class="reference"><sup>a</sup>For patients with carcinoid tumors, starting dosages of Sandostatin Immediate-Release Injection range from 100 mcg/d to 600 mcg/d in 2 to 4 divided doses. For patients with VIPomas, starting dosages range from 200 mcg/d to 300 mcg/d in 2 to 4 divided doses.<sup>1</sup></p>
<p>&nbsp;</p>
<h4 style="margin-bottom: 10px;"><strong>Short-Lived Pain on Injection<sup>1</sup></strong></h4>
<p>Pain on injection, which is generally mild to moderate and short-lived (usually about 1 hour), is dose related. Injection sites should be rotated between the right and left gluteus to avoid irritation.</p>
<ul>
<li>In patients with carcinoid syndrome who kept a diary, pain at the injection site was reported by about 20% to 25% at the 10-mg dose and by about 30% to 50% at the <span style="white-space: nowrap;">20- and 30-mg doses</span></li>
</ul>
<p>&nbsp;</p>
<h4 style="margin-bottom: 10px;"><strong>For Patients Not Currently Receiving Octreotide Acetate<sup>1</sup></strong></h4>
<p>Begin therapy with Sandostatin Immediate-Release Injection and continue for at least 2 weeks.</p>
<table>
<tbody>
<tr>
<td style="color: #6d6e71; background-color: #dadbdd; border: 2px solid #ffffff; width: 25%; padding: 10px;">
<p><strong>For carcinoid tumors</strong></p>
</td>
<td style="background-color: #f0f0f0; border: 2px solid #ffffff; width: 75%; padding: 10px;">
<p>Suggested daily dosage ranges from 100 mcg/d to 600 mcg/d in 2 to 4 divided doses (mean daily dosage is 300 mcg/d) during the first 2 weeks of therapy. Some patients may require doses of up to 1500 mcg/d.</p>
</td>
</tr>
<tr>
<td style="color: #6d6e71; background-color: #dadbdd; border: 2px solid #ffffff; width: 25%; padding: 10px;">
<p><strong>For VIPomas</strong></p>
</td>
<td style="background-color: #f0f0f0; border: 2px solid #ffffff; width: 75%; padding: 10px;">
<p>Suggested daily dose is 200 mcg to 300 mcg in 2 to 4 divided doses (range, 150-750 mcg). Dosages over 450 mcg/d are usually not required. Doses may be adjusted on an individual basis.</p>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h4 style="margin-bottom: 10px;"><strong>Patients Currently Receiving Sandostatin Immediate-Release Injection<sup>1</sup></strong></h4>
<p>Patients who tolerate and are already controlled with Sandostatin Immediate-Release Injection should add Sandostatin LAR Depot according to the dosing regimen described below.</p>
<table>
<tbody>
<tr>
<td style="color: #6d6e71; background-color: #dadbdd; border: 2px solid #ffffff; width: 25%; padding: 10px;">
<p><strong>Add Sandostatin LAR Depot</strong></p>
</td>
<td style="background-color: #f0f0f0; border: 2px solid #ffffff; width: 75%; padding: 10px;">
<ul>
<li>Receive 20-mg dose of Sandostatin LAR Depot intragluteally at 4-week intervals for 2 months</li>
<li>Carcinoid tumor and VIPoma patients should continue to receive their Sandostatin Immediate-Release Injection dose for at least 2 weeks to allow the serum octreotide to reach therapeutically effective levels following initial injection of Sandostatin LAR Depot</li>
<ul>
<li>Failure to continue subcutaneous injections through this period may result in exacerbation of symptoms. (Note: Some patients may require 3 or 4 weeks of such therapy)</li>
</ul>
</ul>
</td>
</tr>
<tr>
<td style="color: #6d6e71; background-color: #dadbdd; border: 2px solid #ffffff; width: 25%; padding: 10px;">
<p><strong>After 2 months, consider dose adjustment</strong></p>
</td>
<td style="background-color: #f0f0f0; border: 2px solid #ffffff; width: 75%; padding: 10px;">
<ul>
<li>Sandostatin LAR Depot 20-mg dose may be increased to 30 mg every 4 weeks if symptoms are not adequately controlled</li>
<li>Patients who achieve good control on a 20-mg dose may have their dose lowered to 10 mg for a trial period. If symptoms recur, dosage should then be increased to 20 mg every 4 weeks; however, many patients can be satisfactorily maintained at a 10-mg dose every 4 weeks</li>
<li>Doses higher than 30 mg are not recommended</li>
</ul>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h4 style="margin-bottom: 10px;"><strong>Dosing for Special Populations<sup>1</sup></strong></h4>
<table>
<tbody>
<tr>
<td style="color: #6d6e71; background-color: #dadbdd; border: 2px solid #ffffff; width: 25%; padding: 10px;">
<p><strong>Renal failure</strong></p>
</td>
<td style="background-color: #f0f0f0; border: 2px solid #ffffff; width: 75%; padding: 10px;">
<p>In patients with renal failure requiring dialysis, the starting dosage should be 10 mg every 4 weeks. In other patients with renal impairment, the starting dosage should be similar to that of a patient without renal failure (ie, 20 mg every 4 weeks).</p>
</td>
</tr>
<tr>
<td style="color: #6d6e71; background-color: #dadbdd; border: 2px solid #ffffff; width: 25%; padding: 10px;">
<p><strong>Hepatic impairment—patients with cirrhosis</strong></p>
</td>
<td style="background-color: #f0f0f0; border: 2px solid #ffffff; width: 75%; padding: 10px;">
<p>In patients with established cirrhosis of the liver, the starting dosage should be 10 mg every 4 weeks.</p>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h4 style="margin-bottom: 10px;"><strong>Assess Therapeutic Efficacy and Safety of Treatment<sup>1</sup></strong></h4>
<p>To assess therapeutic efficacy and safety of treatment, continued patient monitoring is necessary. Be sure to monitor for adverse events that may occur with Sandostatin LAR Depot. See the full Prescribing Information for more information.</p>
<ul>
<li>Cholelithiasis and gallbladder sludge</li>
<li>Blood glucose levels</li>
<li>Vitamin B<sub>12</sub> levels</li>
<li>Serum zinc concentrations in patients receiving total parenteral nutrition (TPN)</li>
<li>Thyroid Function (TSH, total and/or free T4)</li>
<li>5-HIAA, plasma serotonin, and plasma substance P</li>
<li>VIP (plasma vasoactive intestinal peptide)</li>
</ul>
<p>&nbsp;</p>
</div></div><div class="uso-brand-detailcontent">



<a name='mixing--administration'></a>
<main>
	


<h3  class="brandColor">Mixing & Administration</h3>

<h4 ></h4>

<div class="description">
 <p ><p>It is important to closely follow the mixing instructions included in the packaging. Sandostatin LAR Depot must be administered immediately after mixing.<sup>1</sup></p></p>
</div>

<div class="content">
 
</div>




<div class="row">

 


</div>



















</main></div><div class="uso-brand-detailcontent">



<div id="image-full-half-block-71806" class="image-full-half-block" data-hvce="" data-hvce-description="">
 <style>
		#image-full-half-block-71806 .desktopImg {
			display: inline-block;
		}

  #image-full-half-block-71806 .mobileImg {
			display: none;
		}

@media screen and (max-width: 1023px) { #image-full-half-block-71806 .desktopImg { display: none; }  #image-full-half-block-71806 .mobileImg {display: block;}} </style>


  <h3  class="brandColor"></h3>
  <div class="content">

  </div>
<a href="../nurse-center/index.html" target="_self" class="" >

<div class="img-container">
 <img class="img-responsive desktopImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_link_ctas_4.0_mixing_admin_d.jpg" />
  <img class="img-responsive mobileImg" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_link_ctas_4.0_mixing_admin_m.jpg" />
 </div>

</a>
</div></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <p>&nbsp;</p>
<p>Downloadable resources for mixing and administration:</p>
</div></div><div class="uso-brand-detailcontent">


<div class="uso-downloadable-content uso-cpyblk-content clearfix" data-hvce="" data-hvce-description="">
 <figure class="hidden-xs hidden-sm "><img alt="" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_ifu_thumbnail.jpg" height="122" width="122"></figure>
 <div>
  <h4></h4>
  <p></p>
  <p><a class="btn-link uso-cpyblk-link download" target="_blank" href="http://usoncohcp-admin.stage.novartis.episerverhosting.com/globalassets/products/sandostatin-lar/carcinoid/sds-1222252_instructions_for_use.pdf" >Instruction For Use</a></p>
 </div>
</div></div><div class="uso-brand-detailcontent">


<div class="uso-downloadable-content uso-cpyblk-content clearfix" data-hvce="" data-hvce-description="">
 <figure class="hidden-xs hidden-sm "><img alt="" src="../../../../globalassets/products/sandostatin-lar/carcinoid/dosing-administration/110550_mixmat_thumbnail.jpg" height="122" width="122"></figure>
 <div>
  <h4></h4>
  <p></p>
  <p><a class="btn-link uso-cpyblk-link download" target="_blank" href="http://usoncohcp-admin.stage.novartis.episerverhosting.com/globalassets/products/sandostatin-lar/carcinoid/sds-1212874_sandostatin_professional_mixing_mat.pdf" >Step-by-Step Guide to Mixing and Administration</a></p>
 </div>
</div></div><div class="uso-brand-detailcontent">
<div class="uso-cpyblk-content">
 <p><strong>If you still have questions about mixing and/or administration of Sandostatin LAR Depot, please call <span style="white-space: nowrap;">1-888-NOW-NOVA</span> <span style="white-space: nowrap;">(1-888-669-6682)</span>.</strong></p>
<p>&nbsp;</p>
<p class="reference">5-HIAA, 5-hydroxyindoleacetic acid; IR, immediate release; LAR, long-acting release; VIPomas, vasoactive intestinal peptide tumors.</p>
<p class="reference"><strong>Reference:&nbsp;</strong><strong>1. </strong>Sandostatin LAR Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019.</p>
</div></div></div>
 </div>
</div>
<div class="col-isi-content stop-sticky">
  <div class="row">
<div class="col-lg-12">
 <a name="important-safety-info" class="internalAnchor"></a>
 <p class="brandColor"><strong>IMPORTANT SAFETY INFORMATION</strong></p>
<p><strong>Warnings and Precautions</strong></p>
<ul>
<li>Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, pancreatitis, and requiring cholecystectomy in patients taking Sandostatin LAR Depot. Patients should be monitored periodically. If complications of cholelithiasis are suspected, discontinue Sandostatin LAR Depot and treat appropriately</li>
<li>Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly</li>
<li>Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended</li>
<li>Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other ECG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients</li>
<li>Nutrition: Octreotide may alter absorption of dietary fats. Monitoring of vitamin B<sub>12</sub> levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition (TPN) and octreotide should have periodic monitoring of zinc levels</li>
</ul>
<p><strong>Drug Interactions</strong></p>
<ul>
<li>The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution</li>
</ul>
<p><strong>Adverse Reactions</strong></p>
<ul>
<li>The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were biliary abnormalities (62%), injection-site pain (20%-50%), nausea (24%-41%), abdominal pain (10%-35%), fatigue (8%-32%), headache (16%-30%), hyperglycemia (27%), back pain (8%-27%), constipation or vomiting (15%-21%), dizziness (18%-20%), sinus bradycardia (19%), pruritus (18%), upper respiratory tract infection (10%-18%), myalgia (4%-18%), flatulence (9%-16%), arthropathy (8%-15%), rash (15%), generalized pain (4%-15%), sinusitis (5%-12%), conduction abnormalities (9%), hypoglycemia (4%), and arrhythmia (3%)</li>
</ul>
<p><strong>Please see full <a href="https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_lar.pdf" target="_blank" rel="nofollow" data-target="none">Prescribing Information</a>.</strong></p>
<p class="brandColor"><strong>Indications and Usage</strong></p>
<p>Sandostatin<sup>®</sup> LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin<sup>®</sup> (octreotide acetate) Injection has been shown to be effective and tolerated for</p>
<ul>
<li>Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors</li>
<li>Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors</li>
</ul>
<p>In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.</p>
</div>
  </div>


</div>
<div class="col-xs-12">
<ul class='uso-brand-detailmenu mobile visible-xs'>
<li>
<a href="../efficacy/index.html">Efficacy</a>
</li>
<li>
<a href="../safety-profile/index.html">Safety Profile</a>
</li>
<li>
Dosing & Administration
</li>
<li>
<a href="../nurse-center/index.html">On-Demand Training &amp; Resources</a>
</li>
<li>
<a href="../mechanism-of-action/index.html">Mechanism of Action</a>
</li>
<li>
<a href="../access/index.html">Access</a>
</li>
<li>
<a href="../patient-resources/index.html">Patient Resources</a>
</li>
</ul>

</div>

  </div>
<div class="row">
 <div class="col-lg-12 col-md-12">

 </div>
</div>
 </div>
</div>

		</div>
		<div class="container-fluid">
			<div class="row">
				<div>
					<div class="uso-back-to-top hidden-lg text-center">
						<a href="index.html#" onclick="scrollWinTop()"><img src="../../../../Static/img/global/uso-icon-back-to-top.png" /></a> <br />
						<a href="index.html#" onclick="scrollWinTop()" class="uso-btt-link">BACK TO TOP</a>
					</div>
					<div class="uso-back-to-top-lg hidden"></div>
				</div>
			</div>
		</div>
	</main>
	<div><div>
<div style="" class="stop-sticky container-fluid uso-footer">
 <div class="container">
  <div class="row">
<div class="col-lg-12 text-center">
 <div class="uso-ftr-social">
  
  
 </div>
 <div class="uso-ftr-links">
  <p><a class="btn btn-link" href="https://medinfo.novartispharmaceuticals.com/" target="_blank" rel="nofollow" data-target="none">Medical Information</a>&nbsp;<span class="divider">|</span>&nbsp;<a class="btn btn-link" href="https://www.hcp.novartis.com/contact" target="_blank" rel="nofollow" data-target="none">Contact Us</a>&nbsp;<span class="divider">|</span>&nbsp;<a class="btn btn-link" href="http://www.sandostatin.com?non-us" target="_blank" rel="nofollow" data-target="none">Non-US Residents</a>&nbsp;<span class="divider">|</span>&nbsp;<a class="btn btn-link" href="https://www.novartis.us/hcp-privacy-policy#anchor" target="_blank" rel="nofollow" data-target="none">Interest-based Ads</a></p>

 </div>
</div>
  </div>
  <div class="row">
 
<div class="col-lg-6 text-left center-tablet-phone">
 <div class="uso-ftr-logo">
  <a href="https://www.novartis.us/about-us" title="Novartis Oncology" target="_blank" data-target="none"><img src="../../../../globalassets/novartis-logo-111516.svg" alt="Novartis Oncology"></a>
 </div>
</div>
  </div>

  <div class="row">
<div class="col-lg-12 text-left center-tablet-phone">
 <div class="uso-ftr-disclaimer">
  <p>Use of website is governed by the&nbsp;<strong><a class="btn btn-link" href="https://www.novartis.us/terms-use" target="_blank" rel="nofollow" data-target="none">Terms of Use</a></strong>&nbsp;and&nbsp;<strong><a class="btn btn-link" href="https://www.novartis.us/hcp-privacy-policy" target="_blank" rel="nofollow" data-target="none">Privacy Policy</a></strong>.</p>
 </div>
 
</div>
  </div>
  <div class="row">
<div class="col-lg-6 col-xs-12 text-left center-tablet-phone">
 <div class="uso-ftr-copyright">
  <p>Copyright © 2020&nbsp;<a class="btn btn-link" href="https://www.novartis.us/about-us" target="_blank" rel="nofollow" data-target="none">Novartis Pharmaceuticals Corporation</a>. All rights reserved.</p>
 </div>
</div>

<div class="col-lg-6 col-xs-12 text-right center-tablet-phone">
 <div class="uso-ftr-code">
  5/20 SDS-1230251
 </div>
</div>
  </div>
 </div>
</div>

<div id="termsOfuseModal" class="modal fade">
 <div class="modal-dialog">
  <div class="modal-content">
<div class="modal-body">
 
</div>
  </div>
 </div>
</div>

<div id="privacyPolicyModal" class="modal fade">
 <div class="modal-dialog">
  <div class="modal-content">
<div class="modal-body">
 
</div>
  </div>
 </div>
</div></div></div>

	<script src="../../../../bundles/script/master%3Fv=IgwyWqHAVMW8mZv43JHre8PsGfwvmO76Tt124V1TBDo1"></script>


	
 <script src="../../../../bundles/script/brands%3Fv=35NHaC3i5xK1MiMzsewDx66lvpjLyMB4aSozWPFmjmg1"></script>



	<script>
		function scrollWinTop() {
			$(window).scrollTo(0, 500);
			return false;
		}
	</script>
	<div class="container">
		<a href="index.html#" id="uso-sticky-back"><i class="fa fa-angle-up"></i></a>
	</div>



				<div id="interstitialPopUp" class="modal fade">
					<div class="modal-dialog">
						<div class="modal-content">
							<div class="modal-header">
								<button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button>
								<img class="center-block novartis-logo" src="../../../../Static/img/global/Novartis-Logo.svg" />
							</div>
							<div class="modal-body">
								<p>You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or click OK to continue.</p>
							</div>
							<div class="modal-footer">
								<div class="text-center">
									<a class="btn btn-default btn-cancel" data-dismiss="modal"><span>Cancel</span></a>
									<a class="btn btn-continue interstitialOKButton" id="" href="index.html#">OK</a>
								</div>
									<div class="disclaimer-omap">
										1/17  ONC-1154329
									</div>
							</div>
						</div>
					</div>
				</div>


		
</body>





</html>
